$ANL

Adlai Nortye Group Ltd.

Adlai Nortye is a clinical-stage pharmaceutical company focused on discovering and developing cancer therapies. It conducts operations primarily through subsidiaries in the United States and mainland China, with regional headquarters in New Jersey and Hangzhou. Its principal executive office is in the Cayman Islands. Its pipeline includes RAS-targeting candidates AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody drug conjugate carrying a pan-RAS(ON) inhibitor. Its cancer immunotherapy candidates include AN8025, a tri-specific antibody fusion protein, and AN4005, an oral small-molecule PD-L1 inhibitor. AN0025, an in-licensed EP4 antagonist, is being studied as a chemoradiation modulator. Adlai Nortye earns payments under licensing and collaboration agreements, including upfront, development and sales milestones, and royalties. It works with qualified contract manufacturers to supply candidates for preclinical and clinical studies.

No enriched coverage for $ANL in the last 7 days.

No SEC Form 4 filings for $ANL in the last 30 days.

See all $ANL insider activity →
Low

Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data

Roche (RHHBY) and Teva (TEVA) gained FDA approvals for new treatments. Mesa Labs (MLAB) and GSK (GSK) announced job cuts. Labcorp (LH) and AstraZeneca (AZN) made strategic deals. Vir (VIR) partnered with Gilead (GILD) for cancer immunotherapy. Galderma (GALD.SW) to acquire ZO Skin Health for $1.5B. Zealand Pharma (ZEAL.CO) partnered with Generate Biomedicines for AI drug discovery.

Ji Ping sold $163K of ANL

Ji Ping sold 10,214 shares of Adlai Nortye Group Ltd. (ANL) at an average of $15.99 ($15.77–$16.03, $0.16M total) across 3 trades over 2026-09-29 to 2026-09-30.

ANL sentiment & insider activity

Recent ANL coverage spans financial news, insider activity and market movers.

What's driving ANL

AlphAI scores every news story that mentions ANL with an AI model for sentiment and relevance, and aggregates insider trades from Adlai Nortye Group Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ANL

Score

Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data

Roche (RHHBY) and Teva (TEVA) gained FDA approvals for new treatments. Mesa Labs (MLAB) and GSK (GSK) announced job cuts. Labcorp (LH) and AstraZeneca (AZN) made strategic deals. Vir (VIR) partnered with Gilead (GILD) for cancer immunotherapy. Galderma (GALD.SW) to acquire ZO Skin Health for $1.5B. Zealand Pharma (ZEAL.CO) partnered with Generate Biomedicines for AI drug discovery.

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

Adlai Nortye to Participate in Upcoming Investor Conferences

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ: ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of ...

Related tickers